Ulcerative colitis is a chronic inflammatory bowel disease causing inflammation and ulcers in the colon and rectum. It typically follows a relapsing-remitting course with abdominal pain, diarrhea, rectal bleeding, and urgency.
AbbVie posted record 2025 revenue of $61.2 billion and raised 2026 guidance on Skyrizi and Rinvoq growth. Pipeline advances include Crohn's submissions, obesity data, and European approval for Boey.
Abivax aligned with FDA on obefazimod NDA strategy for ulcerative colitis, targeting filing by end‑2026. Phase 3 ABTECT data at ECCO 2026 showed early symptom relief and positive DSMB safety review. Leadership appointments support potential commercialization.
Engineered extracellular vesicles deliver IL-2 and therapeutic antibodies with precision, reducing systemic toxicity and targeting inflamed tissues in autoimmune disease, cancer, and inflammatory bowel disease. Microfluidic electroporation enables efficient IL-2 loading, while exosome nanovesicles show efficacy in preclinical colitis models.
Celltrion released new post-hoc analysis from its phase 3 trial of Remsima SC in IBD patients at the ECCO 2026 congress. The data showed rapid clinical response after treatment gaps and maintained efficacy over 102 weeks. The company also highlighted its unique offering of infliximab in three formulations.
Long-term QUASAR extension data show Tremfya (guselkumab) maintained clinical and endoscopic remission in ulcerative colitis through Week 140, with 80.8% in clinical remission and no new safety signals.
Takeda reported positive ENTYVIO pediatric data, secured FDA Priority Review for oveporexton, and expanded AI drug discovery. Shares trade at ¥5,609; analyst fair value is about ¥5,263.
Two new studies in IBD genetics show that polygenic risk scores can predict disease severity in Danish patients, and that ancestry-specific variants in Hispanic populations reveal novel risk loci and differential effects of known genes. These findings advance precision medicine by improving risk prediction and highlighting the need for diverse genetic research.
Duvakitug showed durable clinical and endoscopic efficacy over 44 weeks in UC and Crohn's patients in a phase 2b LTE study. The results reinforce duvakitug's potential as a best-in-class TL1A therapy. Both doses were well tolerated.
Teva Pharmaceuticals and Sanofi reported positive Phase 2b long-term extension results for duvakitug, a TL1A-targeting monoclonal antibody, showing durable efficacy over 44 weeks in ulcerative colitis and Crohn's disease patients. UC patients achieved up to 58% clinical remission and CD patients up to 55% endoscopic response at the higher dose.
Spyre will present SPY001 topline results in ulcerative colitis on April 13, 2026. Six Phase 2 readouts are expected in 2026; Q1 net loss was $69 million.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07724990 |
A Specific Probiotic in thE MOdulation of Gut Microbiota of patieNts With Mild-to-modErate Ulcerative Colitis |
RECRUITING | NA |
| NCT07697456 |
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07665294 |
Combination CurQD and Vedolizumab in Ulcerative Colitis |
NOT_YET_RECRUITING | PHASE4 |
| NCT07652294 |
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT07619547 |
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease |
NOT_YET_RECRUITING | |
| NCT07521904 |
Naturopathic Approaches to Ulcerative Colitis |
NOT_YET_RECRUITING | |
| NCT07520461 |
Microbiome-targeted Diet Therapy in Ulcerative Colitis |
NOT_YET_RECRUITING | NA |
| NCT07513181 |
Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) |
NOT_YET_RECRUITING | PHASE2 |
| NCT07501078 |
Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation |
RECRUITING | PHASE2 |
| NCT07494227 |
Development of the SC-IBD Self-Care Measurement Scale |
NOT_YET_RECRUITING |
